Jaguar Health, Inc. (NASDAQ:JAGX) Sees Significant Increase in Short Interest

Jaguar Health, Inc. (NASDAQ:JAGX) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 413,000 shares, an increase of 11.4% from the September 15th total of 370,700 shares. Based on an average daily volume of 717,100 shares, the days-to-cover ratio is currently 0.6 days. Currently, 5.3% of the shares of the stock are sold short.

Jaguar Health Price Performance

Shares of NASDAQ:JAGX opened at $1.23 on Thursday. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.10 and a quick ratio of 1.60. Jaguar Health has a 1-year low of $0.95 and a 1-year high of $30.86. The business has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $4.68.

Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($4.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.84). Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. The company had revenue of $2.72 million for the quarter. On average, equities research analysts expect that Jaguar Health will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned 0.51% of Jaguar Health at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Jaguar Health from a “sell” rating to a “hold” rating in a report on Friday, September 13th.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.